Metabolic dysfunction-associated steatotic liver disease-induced changes in the antioxidant system: a review
- PMID: 39443317
- PMCID: PMC11748479
- DOI: 10.1007/s00204-024-03889-x
Metabolic dysfunction-associated steatotic liver disease-induced changes in the antioxidant system: a review
Abstract
Metabolic dysfunction-associated steatotic liver disease (MASLD) is a heterogeneous condition characterized by liver steatosis, inflammation, consequent fibrosis, and cirrhosis. Chronic impairment of lipid metabolism is closely related to oxidative stress, leading to cellular lipotoxicity, mitochondrial dysfunction, and endoplasmic reticulum stress. The detrimental effect of oxidative stress is usually accompanied by changes in antioxidant defense mechanisms, with the alterations in antioxidant enzymes expression/activities during MASLD development and progression reported in many clinical and experimental studies. This review will provide a comprehensive overview of the present research on MASLD-induced changes in the catalytic activity and expression of the main antioxidant enzymes (superoxide dismutases, catalase, glutathione peroxidases, glutathione S-transferases, glutathione reductase, NAD(P)H:quinone oxidoreductase) and in the level of non-enzymatic antioxidant glutathione. Furthermore, an overview of the therapeutic effects of vitamin E on antioxidant enzymes during the progression of MASLD will be presented. Generally, at the beginning of MASLD development, the expression/activity of antioxidant enzymes usually increases to protect organisms against the increased production of reactive oxygen species. However, in advanced stage of MASLD, the expression/activity of several antioxidants generally decreases due to damage to hepatic and extrahepatic cells, which further exacerbates the damage. Although the results obtained in patients, in various experimental animal or cell models have been inconsistent, taken together the importance of antioxidant enzymes in MASLD development and progression has been clearly shown.
Keywords: Antioxidant enzyme; Catalytic activity; Expression; Glutathione; Metabolic dysfunction-associated steatotic liver disease.
© 2024. The Author(s).
Conflict of interest statement
Declarations. Conflict of interest: The authors declare they have no conflict of interest. Ethics approval and consent to participate: Not applicable. Consent for publication: All the authors approved the final version and agreed to publish this work.
Figures


Similar articles
-
Metabolic dysfunction-associated steatotic liver disease: A story of muscle and mass.World J Gastroenterol. 2025 May 28;31(20):105346. doi: 10.3748/wjg.v31.i20.105346. World J Gastroenterol. 2025. PMID: 40495947 Free PMC article.
-
Development of SOCS1 mimetics as novel approach to harmonize inflammation, oxidative stress, and fibrogenesis in metabolic dysfunction-associated steatotic liver disease.Redox Biol. 2025 Jul;84:103670. doi: 10.1016/j.redox.2025.103670. Epub 2025 May 11. Redox Biol. 2025. PMID: 40373621 Free PMC article.
-
ACMSD inhibition corrects fibrosis, inflammation, and DNA damage in MASLD/MASH.J Hepatol. 2025 Feb;82(2):174-188. doi: 10.1016/j.jhep.2024.08.009. Epub 2024 Aug 22. J Hepatol. 2025. PMID: 39181211 Free PMC article.
-
Silymarin for adults with metabolic dysfunction-associated steatotic liver disease.Cochrane Database Syst Rev. 2025 Jun 24;6(6):CD015524. doi: 10.1002/14651858.CD015524.pub2. Cochrane Database Syst Rev. 2025. PMID: 40552569
-
Exploring the role of xanthine oxidase and aldehyde oxidase in metabolic dysfunction-associated steatotic liver disease (MASLD).J Mol Histol. 2025 Jul 23;56(4):237. doi: 10.1007/s10735-025-10507-2. J Mol Histol. 2025. PMID: 40699438 Review.
Cited by
-
Triglyceride-glucose-waist circumference index: A powerful tool for metabolic dysfunction-associated steatotic liver disease.World J Hepatol. 2025 Jul 27;17(7):107668. doi: 10.4254/wjh.v17.i7.107668. World J Hepatol. 2025. PMID: 40747214 Free PMC article. Review.
-
Lifestyle Intervention Improves Metabolic Dysfunction-Associated Steatotic Liver Disease in Children with Down Syndrome.Nutrients. 2025 Jul 16;17(14):2331. doi: 10.3390/nu17142331. Nutrients. 2025. PMID: 40732956 Free PMC article.
-
Protective Effects of Lotus Seedpod Extract on Hepatic Lipid and Glucose Metabolism via AMPK-Associated Mechanisms in a Mouse Model of Metabolic Syndrome and Oleic Acid-Induced HepG2 Cells.Antioxidants (Basel). 2025 May 16;14(5):595. doi: 10.3390/antiox14050595. Antioxidants (Basel). 2025. PMID: 40427477 Free PMC article.
-
Nanotechnology-Based Plant Antioxidants: A Current Literature Review on Bioavailability and Oxidative Stress.Curr Nutr Rep. 2025 Aug 6;14(1):98. doi: 10.1007/s13668-025-00689-2. Curr Nutr Rep. 2025. PMID: 40768104 Review. No abstract available.
-
Extracellular Vesicles as Biomarkers in Chronic Hepatobiliary Diseases: An Overview of Their Interplay.Int J Mol Sci. 2025 Jun 30;26(13):6333. doi: 10.3390/ijms26136333. Int J Mol Sci. 2025. PMID: 40650114 Free PMC article. Review.
References
-
- Adachi T, Wang J, Wang XL (2000) Age-related change of plasma extracellular-superoxide dismutase. Clin Chim Acta 290(2):169–178. 10.1016/s0009-8981(99)00187-4 - PubMed
-
- Alfonso-Prieto M, Biarnés X, Vidossich P, Rovira C (2009) The molecular mechanism of the catalase reaction. J Am Chem Soc 131(33):11751–11761. 10.1021/ja9018572 - PubMed
-
- Ali MH, Messiha BA, Abdel-Latif HA (2016) Protective effect of ursodeoxycholic acid, resveratrol, and N-acetylcysteine on nonalcoholic fatty liver disease in rats. Pharm Biol 54(7):1198–1208. 10.3109/13880209.2015.1060247 - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical